



New Treatment Options for Alzheimer's and Dementia

By **Henrik Hviid**

Portfolio Manager, C WorldWide Asset Management.

For Wholesale Investors only.

Alzheimer's disease was named after Alois Alzheimer, the German psychiatrist who first described the symptoms in 1906. The disease is the most common cause of dementia.

Dementia denotes a condition involving deterioration of mental faculties as a result of the disease. The term dementia comes from Latin and means "without mind". It is uncertain what causes dementia to develop, but it is most likely due to alterations in the brain. More than 200 diseases cause dementia, with Alzheimer's disease accounting for 60-70% of cases. There is currently no cure for the disease, and its progression can range from a few years to several decades until the patient dies from the disease.

The disease is caused by a build-up in the brain of two different proteins, beta-amyloid and tau. Beta-amyloid proteins accumulate between nerve cells, where they cause alterations and inflammation of the brain tissue. Tau proteins accumulate inside the nerve cells, causing damage that render the cells unable to communicate and subsequently destroying them. Alzheimer's disease thus destroys brain cells and causes the patient's brain to shrink. In the early stage of progression, the disease typically affects the areas of the temporal lobe involved in memory. Relatively quickly, other functions, including speech and motor function, also become impaired.

New, innovative Treatments may be on the Way

We have no drugs that can cure Alzheimer's today, but pharmaceutical companies including Eli Lilly, Biogen and Novo Nordisk are attempting to develop innovative new treatments. Eli Lilly and Biogen have developed drug-based treatments aimed at affecting and preventing the brain's production of beta-amyloid proteins, while Novo Nordisk's drug GLP-1 prevents the production of tau proteins and inflammation of nerve cells.


Eli Lilly has successfully tested the efficacy of its drug in a phase 2 trial on a narrow group of patients and is currently in dialogue with the U.S. Food and Drug Administration on the design of the pivotal phase 3 trial.



**More than 200
diseases cause dementia,
with Alzheimer's disease
accounting for 60-70%
of cases. There is
currently no cure.**

Novo Nordisk's GLP-1 products for the treatment of Alzheimer's disease were originally developed to treat diabetes, and over the course of the summer we expect the drug to be approved for treatment of obesity, as well. In treating diabetes patients with GLP-1, Novo Nordisk found that these patients had a significantly lower risk of Alzheimer's and dementia than patients who had not been administered GLP-1 – see figure 1 below.

Figure 1: Lower Risk for Dementia with GLP-1



In three large trials with data from more than 15,000 patients, Novo Nordisk has demonstrated that its GLP-1 drug reduced the risk of dementia by some 50% in these patients. Novo Nordisk has also studied the use of GLP-1 via the Danish nationwide health registry and the US Truven claims database. In the Danish nationwide registry, there were 470,000 observations, and in the US database over 300,000 observations. The conclusion from the two databases is that the Danish data indicate a 25% lower risk of developing dementia after 2.5 years, while the US data indicate about 30% lower risk of dementia after 2 years.

We are closely following the development of new treatment options. Both because the potential demand for a curative drug will be considerable, and because an effective treatment could substantially reduce patient care costs, which are set to rise in the coming decades due to demographic developments.

The authorities' evaluation of Biogen's drug will be known shortly, but there are indications that this treatment may have limited effect. The final trial results from Eli Lilly and Novo Nordisk will not be released for another three years or so, but there will be a great potential for any company that manages to crack the Alzheimer's code. A potential and a success which has so far eluded all.

Facts about Alzheimer's Disease and Dementia

1.

In 2019, the UN estimated that there are over 50 million people living with Alzheimer's or other types of dementia globally. This figure is expected to increase to about 150 million by 2050 due to a combination of a lack of effective treatments and a growing number of elderly people. (Source: WHO)

2.

Alzheimer's and other types of dementia are not only serious conditions for patients and their loved ones, they also take up an enormous amount of healthcare resources. The global cost of treating and caring for Alzheimer's patients is currently about USD 1 trillion. (Source: Patterson C. World Alzheimer Report 2018)

3.

In the USA, the annual cost of care and treatment is some USD 300 billion and is expected to rise to USD 1.1 trillion by 2050. This represents 1.3% of the US GDP, and without new treatments this percentage is set to rise to some 2.2% by 2050. (Source: The US Alzheimer's Association)

4.

At present, there is no cure for Alzheimer's, only various types of drugs that can ease the dementia process.

5.

In the past 25 years, 99.9% of all medical trials for drugs to cure Alzheimer's/dementia have been unsuccessful. At present, there are five approved types of drugs to treat Alzheimer's/dementia, none of which have any significant curative effect. No new drug has been approved since 2003. (Source: FDA)

6.

The three pharmaceutical companies Eli Lilly, Biogen and Novo Nordisk currently have drugs in phase 2 or phase 3 clinical trials. (Source: FDA)



This document has been prepared by C WorldWide Asset Management Fondsmæglerselskab A/S ("C WorldWide"). C WorldWide is regulated by the Danish Financial Services Authority under Danish laws, which differ from Australian laws. In Australia, C WorldWide is exempt from the requirement to hold an Australian Financial Services Licence by operation of ASIC relief. C WorldWide is permitted to provide financial product advice in certain classes of financial products to wholesale clients. This document is distributed in Australia by BNP PARIBAS ASSET MANAGEMENT Australia Limited ABN 78 008 576 449, AFSL 223418 ("BNPP AMAU"). It is produced for general information only for the exclusive use of wholesale investors and does not constitute financial product advice, nor an offer to issue or recommendation to acquire any financial product. You should seek your own professional advice in relation to any financial product referred to.

This document is distributed in New Zealand by BNPP AMAU. BNPP AMAU and C WorldWide are exempt providers under the Financial Advisers Act 2008 that are permitted to provide financial adviser services to wholesale clients as overseas financial advisers as they do not have places of business, and do not provide any financial adviser services to retail clients, in New Zealand. In New Zealand, this document is only being provided to wholesale clients for the purposes of the Financial Advisers Act 2008 (New Zealand).

Any opinions included in this document constitute the judgment of the document's author at the time specified and may be subject to change without notice. Such opinions are not to be relied upon as authoritative or taken in substitution for the exercise of judgment by any recipient and are not intended to provide the sole basis of evaluation of any investment. The contents of this document are based upon sources of information believed to be reliable, but no warranty or declaration, either explicit or implicit, is given as to their accuracy or completeness. BNPP AMAU and C WorldWide, to the extent permitted by law, disclaim all responsibility and liability for any omission, error, or inaccuracy in the information or any action taken in reliance on the information and also for any inaccuracy in the information contained in the document which has been provided by or sourced from third parties. Past performance is not necessarily indicative of future performance. This document may not be copied, distributed or passed on, directly or indirectly, to any person without the express consent of BNPP AMAU and C WorldWide.

BNP PARIBAS ASSET MANAGEMENT Australia Limited
60 Castlereagh Street, Sydney NSW 2000
Tel: 1800 267 726 (Australia) or +61 2 9619 6041 · Fax: +612 9006 9051 · Email: AMAU.ClientService@bnpparibas.com
www.bnpparibas-am.com.au

C WORLDWIDE ASSET MANAGEMENT FONDSMAEGLERSELSKAB A/S
Dampfærgevej 26 · DK-2100 Copenhagen
Tel: +45 35 46 35 00 · Fax: +45 35 46 36 00 · VAT 78 42 05 10 · cworldwide.com
Insight Q2 2021